Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study Journal Article
| Authors: | Tenori, L.; Oakman, C.; Morris, P. G.; Gralka, E.; Turner, N.; Cappadona, S.; Fornier, M.; Hudis, C.; Norton, L.; Luchinat, C.; Di Leo, A. |
| Article Title: | Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study |
| Abstract: | Purpose: Metabolomics is a global study of metabolites in biological samples. In this study we explored whether serum metabolomic spectra could distinguish between early and metastatic breast cancer patients and predict disease relapse.Methods: Serum samples were analysed from women with metastatic (. n=95) and predominantly oestrogen receptor (ER) negative early stage (. n=80) breast cancer using high resolution nuclear magnetic resonance spectroscopy. Multivariate statistics and a Random Forest classifier were used to create a prognostic model for disease relapse in early patients.Results: In the early breast cancer training set (. n=40), metabolomics correctly distinguished between early and metastatic disease in 83.7% of cases. A prognostic risk model predicted relapse with 90% sensitivity (95% CI 74.9-94.8%), 67% specificity (95% CI 63.0-73.4%) and 73% predictive accuracy (95% CI 70.6-74.8%). These results were reproduced in an independent early breast cancer set (. n=40), with 82% sensitivity, 72% specificity and 75% predictive accuracy. Disease relapse was associated with significantly lower levels of histidine (. p=0.0003) and higher levels of glucose (. p=0.01), and lipids (. p=0.0003), compared with patients with no relapse.Conclusions: The performance of a serum metabolomic prognostic model for disease relapse in individuals with ER-negative early stage breast cancer is promising. A confirmation study is ongoing to better define the potential of metabolomics as a host and tumour-derived prognostic tool. |
| Keywords: | adult; cancer chemotherapy; cancer survival; controlled study; aged; cancer surgery; major clinical study; overall survival; cancer recurrence; postoperative period; cancer risk; multimodality cancer therapy; adjuvant therapy; cancer adjuvant therapy; cancer patient; sensitivity and specificity; accuracy; breast cancer; lipid; tyrosine; retrospective study; cancer hormone therapy; blood sampling; early cancer; biomarker; nuclear magnetic resonance spectroscopy; glucose blood level; glucose; amino acid blood level; estrogen receptor; trastuzumab; breast metastasis; lipid blood level; breast surgery; serum; antineoplastic hormone agonists and antagonists; histidine; proton nuclear magnetic resonance; lactic acid; micrometastases; lactate blood level; metabolomics; metabolites; cancer prognosis; human; female; article; random forest |
| Journal Title: | Molecular Oncology |
| Volume: | 9 |
| Issue: | 1 |
| ISSN: | 1878-0261 |
| Publisher: | FEBS Press |
| Date Published: | 2015-01-01 |
| Start Page: | 128 |
| End Page: | 139 |
| Language: | English |
| DOI: | 10.1016/j.molonc.2014.07.012 |
| PROVIDER: | scopus |
| PUBMED: | 25151299 |
| PMCID: | PMC5528693 |
| DOI/URL: | |
| Notes: | Export Date: 2 February 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work